Dr. Reddy’s Laboratories has announced its consolidated financial results for the quarter and year ended March 31, 2026. The company reported full-year revenue of ₹335,933 million, representing a 3.2% year-on-year growth. Despite a challenging Q4 with consolidated revenue at ₹75,162 million, the company remains focused on strengthening its core portfolio through strategic initiatives, portfolio optimization, and long-term investments in biosimilars, consumer health, and innovation.
Financial Performance Summary
For the fiscal year 2026, Dr. Reddy’s reported a gross profit of ₹177,264 million and a profit after tax attributable to equity holders of ₹42,850 million. The full-year results reflect the resilience of the company’s branded businesses, which helped partially mitigate the impact of lower sales of its generic product Lenalidomide and certain one-off adjustments. In Q4, the company recorded a profit attributable to equity holders of ₹2,201 million, with a gross margin of 44.8%.
Segment and Geographic Highlights
The Global Generics segment, which includes the Biologics business, remained a key revenue driver, reporting ₹299,033 million in annual revenue. In India, the company achieved strong performance with ₹62,186 million in revenue, reflecting a 16% year-on-year growth. Meanwhile, the Europe market showed significant potential with a 55% year-on-year revenue increase to ₹55,501 million, supported by contributions from the Nicotine Replacement Therapy (NRT) portfolio.
Strategic Business Updates
The company continued its focus on innovation and portfolio expansion. Key highlights include the launch of generic Semaglutide Injection in India, the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution in the U.S., and the successful integration of 95% of its acquired consumer healthcare business. Furthermore, the board has recommended a final dividend of ₹8 per equity share, with a record date set for July 10, 2026.
Corporate Governance and Leadership
Dr. Reddy’s announced several leadership updates, including the re-appointment of Dr. K P Krishnan as an Independent Director for a second term and the appointment of Mr. Srikanth Velamakanni as an Independent Director. Additionally, Mr. Sandeep Khandelwal has been elevated to the role of Senior Management Personnel and inducted into the Management Council, effective May 12, 2026. The company will also convene its 42nd Annual General Meeting on July 23, 2026.
Source: BSE
